Table 1.

Response rates for all eligible patients contacted as part of the Detroit ROCS Pilot

All patientsNon-Hispanic whiteAfrican American
Number of eligible participants identified1,475633842
Study outcome, N (%)
 Completed interview1,000 (67.8%)414 (65.4%)586 (69.6%)
 Refusal347 (23.5%)162 (25.6%)185 (22.0%)
 Unable to reach91 (6.2%)40 (6.3%)51 (6.1%)
 Unable to locate28 (1.9%)12 (1.9%)16 (1.9%)
 Physician recommended against contact9 (0.6%)5 (0.8%)4 (0.5%)
Response rates, N interviewed (%)
Sex
 Men384 (64.4%)154 (65.0%)230 (64.1%)
 Women616 (70.1%)260 (65.7%)356 (73.7%)
Cancer site
 Breast439 (70.2%)174 (67.2%)265 (72.4%)
 Colorectal101 (66.4%)51 (64.6%)50 (68.5%)
 Lung197 (70.6%)101 (65.2%)96 (77.4%)
 Prostate263 (62.8%)88 (62.9%)175 (62.7%)
SEER summary stage
 Local or regional822 (67.7%)323 (65.0%)499 (69.6%)
 Distant178 (68.2%)91 (66.9%)87 (69.6%)
Among interview respondents, N (%)
Method of completion
 Online307 (30.7%)218 (52.7%)89 (15.2%)
 Telephone693 (69.3%)196 (47.3%)497 (84.8%)
Saliva sample obtained
 No259 (25.9%)102 (24.6%)157 (26.8%)
 Yes741 (74.1%)312 (75.4%)429 (73.2%)
Tumor tissue consent
 No362 (36.2%)130 (31.4%)232 (39.6%)
 Yes638 (63.8%)284 (68.6%)354 (60.4%)